Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well.
Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes.
Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits.
Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems.
Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process.
Alla Zilberman, Vice President, Strategic Marketing and Business Development
Alla leads strategic technical marketing and business development at Cygnus Technologies. Alla joined Cygnus Technologies in 2017 bringing 17 years of experience in product management, strategic marketing and technical sales in the bioprocessing and life science industries. Prior to Cygnus Technologies, Alla spent several years at Semba Biosciences leading commercialization of a disruptive continuous chromatography platform for downstream bioprocessing, and at Novagen/EMD Biosciences, where she was responsible for product management and marketing of tools and technologies for protein expression, purification and sample prep for proteomics research. Alla earned a Ph.D. degree in Biochemistry from the First Moscow Medical Institute and an MBA degree from the University of Cincinnati.